Oncol-话题@MedSci

#Oncol#

2384篇内容 | 2485人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1866602, encodeId=a14b1866602d1, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, objectTitle=JAMA Oncol：Etirinotecan pegol vs 化疗治疗有脑转移的乳腺癌的预后, objectType=article, longId=727101, objectId=5187e27101bb, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5187e27101bb, replyNumber=0, likeNumber=65, createdTime=2022-08-21, rootId=0, userName=minlingfeng, userId=b63894, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5187e27101bb, moduleTitle=JAMA Oncol：Etirinotecan pegol vs 化疗治疗有脑转移的乳腺癌的预后, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5187e27101bb)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1866494, encodeId=4f4e186649471, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, objectTitle=J Thorac Oncol: 探索肺癌生存率性别差异的预后因素, objectType=article, longId=295171, objectId=8e7d2951e11a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8e7d2951e11a, replyNumber=0, likeNumber=91, createdTime=2022-03-01, rootId=0, userName=minlingfeng, userId=b63894, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8e7d2951e11a, moduleTitle=J Thorac Oncol: 探索肺癌生存率性别差异的预后因素, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8e7d2951e11a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1866571, encodeId=a7ed18665e1a5, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, objectTitle=Front Oncol：基于SEER数据库分析II期小肠腺癌(SBA)中切除淋巴结数量的预后作用, objectType=article, longId=301733, objectId=e1e9301e3313, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e1e9301e3313, replyNumber=0, likeNumber=62, createdTime=2022-12-23, rootId=0, userName=minlingfeng, userId=b63894, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e1e9301e3313, moduleTitle=Front Oncol：基于SEER数据库分析II期小肠腺癌(SBA)中切除淋巴结数量的预后作用, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e1e9301e3313)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1866271, encodeId=429118662e150, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, objectTitle=J Clin Oncol：伊布替尼（Ibrutinib）+利妥昔单抗对比安慰剂+ 利妥昔单抗治疗Waldenstrm巨球蛋白血症的疗效:来自随机III期iNNOVATE研究最终分析结果, objectType=article, longId=218141, objectId=54be2181415e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=54be2181415e, replyNumber=0, likeNumber=68, createdTime=2021-11-12, rootId=0, userName=minlingfeng, userId=b63894, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=54be2181415e, moduleTitle=J Clin Oncol：伊布替尼（Ibrutinib）+利妥昔单抗对比安慰剂+ 利妥昔单抗治疗Waldenstrm巨球蛋白血症的疗效:来自随机III期iNNOVATE研究最终分析结果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=54be2181415e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1866378, encodeId=b2d018663e812, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, objectTitle=J Thorac Oncol：Aumolertinib(HS-10296)治疗EGFR-T790M+晚期NSCLC患者的疗效和安全性：APOLLO研究, objectType=article, longId=221184, objectId=7716221184e3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7716221184e3, replyNumber=0, likeNumber=61, createdTime=2022-06-20, rootId=0, userName=minlingfeng, userId=b63894, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7716221184e3, moduleTitle=J Thorac Oncol：Aumolertinib(HS-10296)治疗EGFR-T790M+晚期NSCLC患者的疗效和安全性：APOLLO研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7716221184e3)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1866260, encodeId=32ae1866260e4, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, objectTitle=Front Oncol：贝伐单抗或帕博利珠单抗联合培美曲塞+铂类化疗一线治疗驱动基因阴性晚期非鳞非小细胞肺癌(NSCLC)的直接疗效对比, objectType=article, longId=217997, objectId=faae21e997e8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=faae21e997e8, replyNumber=0, likeNumber=108, createdTime=2022-07-23, rootId=0, userName=minlingfeng, userId=b63894, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=faae21e997e8, moduleTitle=Front Oncol：贝伐单抗或帕博利珠单抗联合培美曲塞+铂类化疗一线治疗驱动基因阴性晚期非鳞非小细胞肺癌(NSCLC)的直接疗效对比, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=faae21e997e8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1866430, encodeId=52a51866430f0, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, objectTitle=Front Oncol：TACE联合仑伐替尼(TACE- L) vs TACE联合索拉非尼(TACE- S)治疗肝细胞癌(HCC)伴有门静脉癌栓(PVTT)患者的疗效和安全性, objectType=article, longId=292954, objectId=a2d3292954c0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a2d3292954c0, replyNumber=0, likeNumber=50, createdTime=2022-08-09, rootId=0, userName=minlingfeng, userId=b63894, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a2d3292954c0, moduleTitle=Front Oncol：TACE联合仑伐替尼(TACE- L) vs TACE联合索拉非尼(TACE- S)治疗肝细胞癌(HCC)伴有门静脉癌栓(PVTT)患者的疗效和安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a2d3292954c0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1866394, encodeId=21ea18663941c, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, objectTitle=J Clin Oncol：CHOP方案加用罗米地辛治疗复发/难治性外周T细胞淋巴瘤的疗效和安全性, objectType=article, longId=221472, objectId=77c32214e24c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=77c32214e24c, replyNumber=0, likeNumber=88, createdTime=2021-12-14, rootId=0, userName=minlingfeng, userId=b63894, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=77c32214e24c, moduleTitle=J Clin Oncol：CHOP方案加用罗米地辛治疗复发/难治性外周T细胞淋巴瘤的疗效和安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=77c32214e24c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1866446, encodeId=17521866446d8, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, objectTitle=Ther Adv Med Oncol：Bendamustine (苯达莫司汀)联合卡培他滨治疗经治的HER2阴性乳腺癌患者的疗效, objectType=article, longId=293430, objectId=627129343025, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=627129343025, replyNumber=0, likeNumber=92, createdTime=2022-10-28, rootId=0, userName=minlingfeng, userId=b63894, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=627129343025, moduleTitle=Ther Adv Med Oncol：Bendamustine (苯达莫司汀)联合卡培他滨治疗经治的HER2阴性乳腺癌患者的疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=627129343025)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1866516, encodeId=418d18665163c, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, objectTitle=J Clin Oncol：反种族主义干预对肺癌手术的种族差异的影响, objectType=article, longId=299131, objectId=66db29913183, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=66db29913183, replyNumber=0, likeNumber=71, createdTime=2022-12-22, rootId=0, userName=minlingfeng, userId=b63894, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=66db29913183, moduleTitle=J Clin Oncol：反种族主义干预对肺癌手术的种族差异的影响, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=66db29913183)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1866220, encodeId=fe2d1866220b2, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, objectTitle=Lancet Oncol：Tisagenlecleucel用于难治/复发性侵袭性B细胞淋巴瘤的长期临床预后, objectType=article, longId=217065, objectId=6c6c21e06592, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6c6c21e06592, replyNumber=0, likeNumber=62, createdTime=2022-02-20, rootId=0, userName=爆笑小医, userId=395f25, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6c6c21e06592, moduleTitle=Lancet Oncol：Tisagenlecleucel用于难治/复发性侵袭性B细胞淋巴瘤的长期临床预后, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6c6c21e06592)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1866471, encodeId=5fb618664e197, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, objectTitle=J Clin Oncol：三阴性乳腺癌新辅助化疗加入卡铂或贝伐珠单抗并不能改善患者的长期预后（LTOs）, objectType=article, longId=294716, objectId=db94294e16ed, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=db94294e16ed, replyNumber=0, likeNumber=90, createdTime=2022-02-09, rootId=0, userName=minlingfeng, userId=b63894, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=db94294e16ed, moduleTitle=J Clin Oncol：三阴性乳腺癌新辅助化疗加入卡铂或贝伐珠单抗并不能改善患者的长期预后（LTOs）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=db94294e16ed)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1866586, encodeId=3691186658647, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, objectTitle=J Clin Oncol：EGFR抑制剂治疗EGFR扩增的胃食管交界癌的疗效, objectType=article, longId=724167, objectId=fa55e2416717, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fa55e2416717, replyNumber=0, likeNumber=0, createdTime=2023-02-22, rootId=0, userName=minlingfeng, userId=b63894, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fa55e2416717, moduleTitle=J Clin Oncol：EGFR抑制剂治疗EGFR扩增的胃食管交界癌的疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=fa55e2416717)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1866405, encodeId=8ed518664053a, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, objectTitle=Front Oncol：立体定向放疗（SBRT）联合免疫治疗（SBRT-IO）对比TACE治疗局部进展期肝细胞癌患者的疗效, objectType=article, longId=264987, objectId=306f26498e26, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=306f26498e26, replyNumber=0, likeNumber=81, createdTime=2022-03-05, rootId=0, userName=minlingfeng, userId=b63894, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=306f26498e26, moduleTitle=Front Oncol：立体定向放疗（SBRT）联合免疫治疗（SBRT-IO）对比TACE治疗局部进展期肝细胞癌患者的疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=306f26498e26)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1866352, encodeId=75e51866352bc, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, objectTitle=Front Oncol：阿帕替尼治疗多线治疗进展的转移性乳腺癌患者的安全性和有效性, objectType=article, longId=220491, objectId=63e622049190, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=63e622049190, replyNumber=0, likeNumber=62, createdTime=2022-03-10, rootId=0, userName=minlingfeng, userId=b63894, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=63e622049190, moduleTitle=Front Oncol：阿帕替尼治疗多线治疗进展的转移性乳腺癌患者的安全性和有效性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=63e622049190)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1866316, encodeId=143b18663166c, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, objectTitle=Front Oncol：TACE联合索拉非尼或阿帕替尼治疗伴有门脉癌栓（PVTT）的肝细胞癌（HCC）患者的疗效, objectType=article, longId=219192, objectId=ab6d21919256, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ab6d21919256, replyNumber=0, likeNumber=104, createdTime=2021-12-24, rootId=0, userName=minlingfeng, userId=b63894, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ab6d21919256, moduleTitle=Front Oncol：TACE联合索拉非尼或阿帕替尼治疗伴有门脉癌栓（PVTT）的肝细胞癌（HCC）患者的疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ab6d21919256)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1866205, encodeId=03d3186620568, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, objectTitle=J Clin Oncol：肌层浸润性膀胱癌根治性切除术前予以吉西他滨+顺铂+派姆单抗新辅助疗法的效果, objectType=article, longId=216311, objectId=0e3021631188, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0e3021631188, replyNumber=0, likeNumber=64, createdTime=2022-08-07, rootId=0, userName=minlingfeng, userId=b63894, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0e3021631188, moduleTitle=J Clin Oncol：肌层浸润性膀胱癌根治性切除术前予以吉西他滨+顺铂+派姆单抗新辅助疗法的效果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0e3021631188)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1866315, encodeId=4cd118663150f, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, objectTitle=Front Oncol：卡瑞利珠单抗联合索拉非尼vs 索拉非尼单药治疗晚期肝细胞癌（HCC）的有效性和安全性, objectType=article, longId=219191, objectId=02ce219191a0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=02ce219191a0, replyNumber=0, likeNumber=60, createdTime=2021-12-11, rootId=0, userName=minlingfeng, userId=b63894, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=02ce219191a0, moduleTitle=Front Oncol：卡瑞利珠单抗联合索拉非尼vs 索拉非尼单药治疗晚期肝细胞癌（HCC）的有效性和安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=02ce219191a0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1866351, encodeId=53891866351ae, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, objectTitle=HEMATOLOGICAL ONCOLOGY：支气管镜检查对新诊断的急性白血病患者的应用, objectType=article, longId=220342, objectId=0eee22034257, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0eee22034257, replyNumber=0, likeNumber=72, createdTime=2022-03-05, rootId=0, userName=minlingfeng, userId=b63894, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0eee22034257, moduleTitle=HEMATOLOGICAL ONCOLOGY：支气管镜检查对新诊断的急性白血病患者的应用, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0eee22034257)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1866183, encodeId=11a51866183f6, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, objectTitle=The Oncologist：转移性尿路上皮癌铂类为基础化疗进展后再挑战的疗效, objectType=article, longId=215461, objectId=9370215461b2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9370215461b2, replyNumber=0, likeNumber=138, createdTime=2021-11-21, rootId=0, userName=minlingfeng, userId=b63894, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9370215461b2, moduleTitle=The Oncologist：转移性尿路上皮癌铂类为基础化疗进展后再挑战的疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9370215461b2)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

Oncol

2020-05-29

minlingfeng (审核中...)

前往app查看评论内容

#Oncol#

JAMA Oncol：Etirinotecan pegol vs 化疗治疗有脑转移的乳腺癌的预后

2022-08-21

minlingfeng (审核中...)

前往app查看评论内容

#Oncol#

J Thorac Oncol: 探索肺癌生存率性别差异的预后因素

2022-03-01

minlingfeng (审核中...)

前往app查看评论内容

#Oncol#

Front Oncol：基于SEER数据库分析II期小肠腺癌(SBA)中切除淋巴结数量的预后作用

2022-12-23

minlingfeng (审核中...)

前往app查看评论内容

#Oncol#

J Clin Oncol：伊布替尼（Ibrutinib）+利妥昔单抗对比安慰剂+ 利妥昔单抗治疗Waldenstrm巨球蛋白血症的疗效:来自随机III期iNNOVATE研究最终分析结果

2021-11-12

minlingfeng (审核中...)

前往app查看评论内容

#Oncol#

J Thorac Oncol：Aumolertinib(HS-10296)治疗EGFR-T790M+晚期NSCLC患者的疗效和安全性：APOLLO研究

2022-06-20

minlingfeng (审核中...)

前往app查看评论内容

#Oncol#

Front Oncol：贝伐单抗或帕博利珠单抗联合培美曲塞+铂类化疗一线治疗驱动基因阴性晚期非鳞非小细胞肺癌(NSCLC)的直接疗效对比

2022-07-23

minlingfeng (审核中...)

前往app查看评论内容

#Oncol#

Front Oncol：TACE联合仑伐替尼(TACE- L) vs TACE联合索拉非尼(TACE- S)治疗肝细胞癌(HCC)伴有门静脉癌栓(PVTT)患者的疗效和安全性

2022-08-09

minlingfeng (审核中...)

前往app查看评论内容

#Oncol#

J Clin Oncol：CHOP方案加用罗米地辛治疗复发/难治性外周T细胞淋巴瘤的疗效和安全性

2021-12-14

minlingfeng (审核中...)

前往app查看评论内容

#Oncol#

Ther Adv Med Oncol：Bendamustine (苯达莫司汀)联合卡培他滨治疗经治的HER2阴性乳腺癌患者的疗效

2022-10-28

minlingfeng (审核中...)

前往app查看评论内容

#Oncol#

J Clin Oncol：反种族主义干预对肺癌手术的种族差异的影响

2022-12-22

爆笑小医 (审核中...)

前往app查看评论内容

#Oncol#

Lancet Oncol：Tisagenlecleucel用于难治/复发性侵袭性B细胞淋巴瘤的长期临床预后

2022-02-20

minlingfeng (审核中...)

前往app查看评论内容

#Oncol#

J Clin Oncol：三阴性乳腺癌新辅助化疗加入卡铂或贝伐珠单抗并不能改善患者的长期预后（LTOs）

2022-02-09

minlingfeng (审核中...)

前往app查看评论内容

#Oncol#

J Clin Oncol：EGFR抑制剂治疗EGFR扩增的胃食管交界癌的疗效

2023-02-22

minlingfeng (审核中...)

前往app查看评论内容

#Oncol#

Front Oncol：立体定向放疗（SBRT）联合免疫治疗（SBRT-IO）对比TACE治疗局部进展期肝细胞癌患者的疗效

2022-03-05

minlingfeng (审核中...)

前往app查看评论内容

#Oncol#

Front Oncol：阿帕替尼治疗多线治疗进展的转移性乳腺癌患者的安全性和有效性

2022-03-10

minlingfeng (审核中...)

前往app查看评论内容

#Oncol#

Front Oncol：TACE联合索拉非尼或阿帕替尼治疗伴有门脉癌栓（PVTT）的肝细胞癌（HCC）患者的疗效

2021-12-24

minlingfeng (审核中...)

前往app查看评论内容

#Oncol#

J Clin Oncol：肌层浸润性膀胱癌根治性切除术前予以吉西他滨+顺铂+派姆单抗新辅助疗法的效果

2022-08-07

minlingfeng (审核中...)

前往app查看评论内容

#Oncol#

Front Oncol：卡瑞利珠单抗联合索拉非尼vs 索拉非尼单药治疗晚期肝细胞癌（HCC）的有效性和安全性

2021-12-11

minlingfeng (审核中...)

前往app查看评论内容

#Oncol#

HEMATOLOGICAL ONCOLOGY：支气管镜检查对新诊断的急性白血病患者的应用

2022-03-05

minlingfeng (审核中...)

前往app查看评论内容

#Oncol#

The Oncologist：转移性尿路上皮癌铂类为基础化疗进展后再挑战的疗效

2021-11-21

科室
- - 订阅+
  - 更多科室
工具
服务